AYTU BioPharmaAYTU
About: Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
Employees: 102
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
11% less funds holding
Funds holding: 27 [Q2] → 24 (-3) [Q3]
19.31% less ownership
Funds ownership: 52.61% [Q2] → 33.31% (-19.31%) [Q3]
48% less capital invested
Capital invested by funds: $9.17M [Q2] → $4.81M (-$4.36M) [Q3]
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for AYTU.
Financial journalist opinion
Based on 3 articles about AYTU published over the past 30 days
